1. Home
  2. RVPH vs SWAG Comparison

RVPH vs SWAG Comparison

Compare RVPH & SWAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • SWAG
  • Stock Information
  • Founded
  • RVPH 2006
  • SWAG 1994
  • Country
  • RVPH United States
  • SWAG United States
  • Employees
  • RVPH N/A
  • SWAG N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • SWAG Advertising
  • Sector
  • RVPH Health Care
  • SWAG Consumer Discretionary
  • Exchange
  • RVPH Nasdaq
  • SWAG Nasdaq
  • Market Cap
  • RVPH 30.1M
  • SWAG 30.4M
  • IPO Year
  • RVPH N/A
  • SWAG 2021
  • Fundamental
  • Price
  • RVPH $0.40
  • SWAG $1.89
  • Analyst Decision
  • RVPH Strong Buy
  • SWAG
  • Analyst Count
  • RVPH 5
  • SWAG 0
  • Target Price
  • RVPH $5.20
  • SWAG N/A
  • AVG Volume (30 Days)
  • RVPH 1.3M
  • SWAG 128.0K
  • Earning Date
  • RVPH 11-13-2025
  • SWAG 11-06-2025
  • Dividend Yield
  • RVPH N/A
  • SWAG N/A
  • EPS Growth
  • RVPH N/A
  • SWAG N/A
  • EPS
  • RVPH N/A
  • SWAG N/A
  • Revenue
  • RVPH N/A
  • SWAG $108,405,000.00
  • Revenue This Year
  • RVPH N/A
  • SWAG N/A
  • Revenue Next Year
  • RVPH N/A
  • SWAG N/A
  • P/E Ratio
  • RVPH N/A
  • SWAG N/A
  • Revenue Growth
  • RVPH N/A
  • SWAG 38.74
  • 52 Week Low
  • RVPH $0.30
  • SWAG $0.73
  • 52 Week High
  • RVPH $4.28
  • SWAG $1.96
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 34.75
  • SWAG 62.49
  • Support Level
  • RVPH $0.50
  • SWAG $1.79
  • Resistance Level
  • RVPH $0.47
  • SWAG $1.96
  • Average True Range (ATR)
  • RVPH 0.03
  • SWAG 0.09
  • MACD
  • RVPH -0.01
  • SWAG 0.00
  • Stochastic Oscillator
  • RVPH 14.30
  • SWAG 79.35

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.

Share on Social Networks: